NeuroPhage is initially developing drug candidates to treat Alzheimer's and Parkinson's diseases, in which multiple misfolded proteins can exacerbate disease progression, and the Company is also targeting several rare
systemic amyloidosis diseases.
NeuroPhage is initially developing drug candidates to treat Alzheimer's and Parkinson's diseases and several rare
systemic amyloidosis diseases.
Accumulation of misfolded protein aggregates is not only present in T2D but also is the main feature of a group of diseases known as protein misfolding disorders (PMDs), including various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and prion disorders, as well as several
systemic amyloidosis disease (Luheshi et al., 2008; Soto and Estrada, 2008).
Not exact matches
Indeed, a series of recent, exciting studies have shown that the pathologic hallmarks of various PMDs, including Alzheimer's, Parkinson's, Huntington's
diseases, and some forms of
systemic amyloidosis, can be induced under experimental conditions by administration of tissue homogenates carrying the respective misfolded proteins (Xing et al., 2001; Lundmark et al., 2002; Meyer - Luehmann et al., 2006; Clavaguera et al., 2009; Ren et al., 2009; Eisele et al., 2010; Grad et al., 2011; Luk et al., 2012; Morales et al., 2012; Mougenot et al., 2012; Stöhr et al., 2012; Iba et al., 2013).
Immune - mediated polyarthritis and
systemic disease including
amyloidosis has been reported in Akita dogs following modified live vaccination.
Lysosomal storage
diseases such as Niemann - Pick
disease, mucopolysaccharidosis and gangliosidosis (GM1) have been described in Siamese cats, as has
systemic amyloidosis.